Pathological assessment of post-treatment gastrointestinal and hepatic resection specimens

Current Diagnostic Pathology

Volumn 13, Issue 3, 2007, Pages 222-231

  Wang, Lai Mun ^a   Sheahan, Kieran ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Chemoradiotherapy; Neoadjuvant therapy; Post treatment pathological change

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CISPLATIN; FLUOROURACIL; FOLINIC ACID; IMATINIB; IRINOTECAN; OXALIPLATIN;

ARTICLE; ASPIRATION BIOPSY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER STAGING; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; ENDOSCOPIC BIOPSY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CANCER; LIVER METASTASIS; LIVER RESECTION; MICROSCOPY; RECTUM CARCINOMA; STROMA; TUMOR CELL; TUMOR VOLUME;

EID: 34250777935     PISSN: 09686053     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cdip.2007.04.006     Document Type: Article

References (54)

1. Lowichik A., Zhou H., Pysher T.J., et al. Therapy associated changes in childhood tumors. Adv Anat Pathol 7 (2000) 341-359
2. Quirke P., Durdey P., Dixon M.F., and Williams N.S. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 2 (1986) 996-999
3. Pasetto L.M., Pucciarelli S., Agostini M., et al. Neoadjuvant treatment for locally advanced rectal carcinoma. Crit Rev Oncol Hematol 52 (2004) 61-71
4. Bouzourene H., Bosman F.T., Seelentag W., Matter M., and Coucke P. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 94 (2002) 1121-1130
5. Wheeler J.M., Dodds E., Warren B.F., et al. Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade. Dis Colon Rectum 47 (2004) 2025-2031
6. Pucciarelli S., Toppan P., Friso L.M., et al. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome. Dis Colon Rectum 47 (2004) 1798-1807
7. Guillem J.G., Chessin D.B., Cohen A.M., et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg 241 (2005) 829-836
8. Nagtegaal I.D., Marijnen C.A.M., Kranenbarg E.K., et al. Short-term preoperative radiotherapy interferes with the determination of pathological parameters in rectal cancer. J Pathol 197 (2002) 20-27
9. Francois Y., Nemoz C.J., Baulieux J., et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: The Lyon R90-01 Randomized Trial. J Clin Oncol 17 (1999) 2396-2402
10. Ruo L., Tickoo S., Klimstra D.S., et al. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg 236 (2002) 75-81
11. Shia J., Guillem J.G., Moore H.G., et al. Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. Am J Surg Pathol 28 (2004) 215-223
12. Theodoropoulos G., Wise W.E., Padmanabhan A., et al. T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 45 (2002) 895-903
13. Shepherd N.A., Baxter K.J., and Love S.B. Influence of local peritoneal involvement on pelvic recurrence and prognosis in rectal cancer. J Clin Pathol 48 (1995) 849-855
14. Wichmann M.W., Müller C., Meyer G., et al. Effect of preoperative radiochemotherapy on lymph node retrieval after resection of rectal cancer. Arch Surg 137 (2002) 206-210
15. Luna-Pérez P., Rodríguez-Ramírez S., Alvarado I., Gutiérrez de la Barrera M., and Labastida S. Prognostic significance of retrieved lymph nodes per specimen in resected rectal adenocarcinoma after preoperative chemoradiation therapy. Arch Med Res 34 (2003) 281-286
16. Scott K.W., Grace R.H., and Gibbons P. Five-year follow-up study of the fat clearance technique in colorectal carcinoma. Dis Colon Rectum 37 (1994) 126-128
17. Redston M. Epithelial neoplasms of the large intestine. In: Odze R.D., Goldblum J.R., and Crawford J.M. (Eds). Surgical pathology of the GI tract, liver, biliary tract, and pancreas (2004), WB Saunders, Philadelphia 463-464
18. Compton C.C., Fielding L.P., Burgart L.J., et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124 (2000) 979-994
19. Greene FL, Page DL, Flemming ID, et al., editors. AJCC cancer staging manual. 6th ed. New York: Springer, 2002.
20. Ryan R., Gibbons D., Hyland J.M., et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 47 (2005) 141-146
21. Chan A.K., Wong A., Jenken D., Heine J., Buie D., and Johnson D. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 61 (2005) 665-677
22. Nagtegaal I.D., Marijnen C.A., Kranenbarg E.K., et al. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol 26 (2002) 350-357
23. Luna-Perez P., Bustos-Cholico E., Alvarado I., et al. Prognostic significance of circumferential margin involvement in rectal adenocarcinoma treated with preoperative chemoradiotherapy and low anterior resection. J Surg Oncol 90 (2005) 20-25
24. Mawdsley S., Glynne-Jones R., Grainger J., et al. Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?. Int J Radiat Oncol Biol Phys 63 (2005) 745-752
25. Dworak O., Keilholz L., and Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12 (1997) 19-23
26. Mandard A.M., Dalibard F., Mandard J.C., et al. Pathologic assessment of tumour regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer 73 (1994) 2680-2686
27. Wheeler J.M., Warren B.F., Mortensen N.J., et al. Quantification of histologic regression of rectal cancer after irradiation: a proposal for a modified staging system. Dis Colon Rectum 45 (2002) 1051-1056
28. Gignoux M., Roussel A., Paillot B., et al. The value of preoperative radiotherapy in esophageal cancer: results of a study of the E.O.R.T.C. World J Surg 11 (1987) 426-432
29. Kelsen D.P., Ginsberg R., Pajak T.G., et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339 (1998) 1979-1984
30. Ancona E., Ruol A., Santi S., et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma. Cancer 91 (2001) 2165-2174
31. Bosset J.F., Gignoux M., Triboulet J.P., et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. N Engl J Med 337 (1997) 161-167
32. Urba S.G., Orringer M.B., Turrisi A., et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional oesophageal carcinoma. J Clin Oncol 19 (2001) 305-313
33. Walsh T.N., Noonan N., Hollywood D., et al. A comparison of multimodal therapy and surgery for oesophageal adenocarcinoma. N Engl J Med 335 (1996) 462-467
34. Malthaner R.A., Wong R.K., Rumble R.B., et al. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2 (2004) 35
35. Dunne B., Reynolds J.V., Mulligan E., Kelly A., and Griffin M. A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy. J Clin Pathol 54 (2001) 841-845
36. Chirieac L.R., Swisher S.G., Correa A.M., et al. Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma. Clin Cancer Res 11 (2005) 2229-2236
37. Hornick J.L., Farraye F.A., and Odze R.D. Prevalence and significance of prominent mucin pools in the esophagus post neoadjuvant chemoradiotherapy for Barrett's-associated adenocarcinoma. Am J Surg Pathol 30 (2006) 28-35
38. Chirieac L.R., Swisher S.G., Ajani A.J., et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 103 (2005) 1347-1355
39. Donington J.S., Miller D.L., Allen M.S., Deschamps C., Nichols F.C., and Pairolero P.C. Tumor response to induction chemoradiation: influence on survival after esophagectomy. Eur J Cardiothorac Surg 24 (2003) 631-637
40. Yano M., Yasuda T., Miyata H., Fujiwara Y., Takiguchi S., and Monden M. Correlation between histological effects on the main tumors and nodal status after chemoradiotherapy for squamous cell carcinoma of the esophagus. J Surg Oncol 89 (2005) 244-250
41. Slater M.S., Holland J., Faigel D.O., Sheppard B.C., and Deveney C.W. Does neoadjuvant chemoradiation downstage esophageal carcinoma?. Am J Surg 181 (2001) 440-444
42. Burmeister B.H., Smithers B.M., Gebski V., et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 6 (2005) 659-668
43. Japanese Society for Esophageal Disease. Pathological classification. In: Guidelines for clinical and pathologic studies on carcinoma of the oesophagus. 8th ed. Tokyo: Kanehara; 1992. p. 59-93.
44. Gu Y., Swisher S.G., Ajani J.A., et al. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer 106 (2006) 1017-1025
45. Ludeman L., and Shepherd N.A. Serosal involvement in gastrointestinal cancer: its assessment and significance. Histopathology 47 (2005) 123-131
46. Bismuth H., Adam R., Lévi F., et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224 (1996) 509-522
47. Folprecht G., Grothey A., Alberts S., Raab H.R., and Kohne C.H. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16 (2005) 1311-1319
48. Folprecht G., Lutz M.P., Schöffski P., et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17 (2006) 450-456
49. Adam R., Avisar E., Ariche A., et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 8 (2001) 347-353
50. Nagashima I., Oka T., Namada C., Naruse K., Osada T., and Muto T. Histopathological prognostic factors influencing long-term prognosis after surgical resection for hepatic metastases from colorectal cancer. Am J Gastroenterol 94 (1999) 739-743
51. Giacchetti S., Itzhaki M., Gruia G., et al. Long term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10 (1999) 663-669
52. Znajda T.L., Hayashi S., Horton P.J., et al. Postchemotherapy characteristics of hepatic colorectal metastases: remnants of uncertain malignant potential. J Gastrointest Surg 10 (2006) 483-489
53. Kim H.C., Lee J.M., Choi S.H., et al. Cystic changes in intraabdominal extrahepatic metastases from gastrointestinal stromal tumors treated with imatinib. Korean J Radiol 5 (2004) 157-163
54. Loughrey M.B., Mitchell C., Mann G.B., Michael M., and Waring P.M. Gastrointestinal stromal tumour treated with neoadjuvant imatinib. J Clin Pathol 58 (2005) 779-781